

8-15-2025

## Synthesis, Biological Activity and Molecular Docking Study of Some New Chalcones, 5,6-dihydropyrimidin-2-ol and 5,6-dihydropyrimidin-2-thiol Derivatives Bearing 1,2,3- Triazoline

Hayder Raheem Ali

*Department of chemistry, College of Science, University of Karbala, Karbala, Iraq.,*  
hayder.raheem@uokerbala.edu.iq

Ahmed Wahed Naser

*Department of chemistry, College of Science, University of Baghdad, Baghdad, Iraq.,*  
ahmedwahed@uobaghdad.edu.iq

Follow this and additional works at: <https://bsj.uobaghdad.edu.iq/home>

---

### How to Cite this Article

Ali, Hayder Raheem and Naser, Ahmed Wahed (2025) "Synthesis, Biological Activity and Molecular Docking Study of Some New Chalcones, 5,6-dihydropyrimidin-2-ol and 5,6-dihydropyrimidin-2-thiol Derivatives Bearing 1,2,3- Triazoline," *Baghdad Science Journal*: Vol. 22: Iss. 8, Article 3.  
DOI: <https://doi.org/10.21123/2411-7986.5013>

This Article is brought to you for free and open access by Baghdad Science Journal. It has been accepted for inclusion in Baghdad Science Journal by an authorized editor of Baghdad Science Journal.



## RESEARCH ARTICLE

# Synthesis, Biological Activity and Molecular Docking Study of Some New Chalcones, 5,6-Dihydropyrimidin-2-Ol and 5,6-Dihydropyrimidin-2-Thiol Derivatives Bearing 1,2,3-Triazoline

Hayder Raheem Ali<sup>1,\*</sup>, Ahmed Wahed Naser<sup>2</sup><sup>1</sup> Department of Chemistry, College of Science, University of Karbala, Karbala, Iraq<sup>2</sup> Department of Chemistry, College of Science, University of Baghdad, Baghdad, Iraq

## ABSTRACT

Many new chemicals, including chalcones, derivatives of 5,6-dihydropyrimidin-2-ol and 5,6-dihydropyrimidin-2-thiol, are synthesized in this work. The starting materials are substituted acetophenone derivatives involving 1,2,3-triazoline (1). Chalcone derivatives (2a–h) were obtained by condensing compound (1) with some substituted aromatic aldehydes in the presence of 40% potassium hydroxide KOH. The process of producing pyrimidin-2-ol derivatives (3a–e) by cyclizing produced chalcone derivatives (2a–e) urea in the presence of sodium hydroxide. Equivalent pyrimidin-2-thiol derivatives (4a–d) were produced when chalcone derivatives (2a–d) reacted with thiourea in the presence of sodium hydroxide. The target compounds are characterized using <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, and FT-IR. The findings demonstrate the target compounds' strong biological activity, including their antioxidant and antibacterial properties. The studies on molecular docking.

**Keywords:** Antibacterial, Antioxidants, Chalcone, Molecular docking, Pyrimidine

## Introduction

Heterocyclic compounds are those that have atoms other than carbon in their complicated toroidal component. Sulfur, oxygen, and nitrogen are the most prevalent heterogeneous atoms. These substances are significant since nature contains a number of biologically active natural products.<sup>1</sup> One of the flavonoid familial subcategories, chalcones are flavonoids but open-chain with two aromatic rings linked to an  $\alpha$ ,  $\beta$ -unsaturated enone.<sup>2</sup> Because chalcones are utilized as intermediates in the synthesis of numerous heterocyclic chemicals, their manufacture is crucial to industry.<sup>3</sup> There are numerous ways to syn-

thesize chalcones. Chalcones were often made by benzaldehyde derivatives acting as electrophiles and acetophenone derivatives acting as a nucleophiles by a Claisen-Schmidt condensation reaction with bases such as NaOH, KOH, and Ba(OH)<sub>2</sub>.<sup>4</sup> The biological activities of chalcones and their derivatives were observed, such as antibacterial,<sup>5</sup> anti-inflammatory,<sup>6</sup> anti-ulcer,<sup>7</sup> antidepressant,<sup>8</sup> antioxidant,<sup>9</sup> and anti-cancer.<sup>10</sup> Pyrimidine is an important six-membered diazaheterocycle, wherein two nitrogen atoms occupy 1 and 3 positions in the ring.<sup>11</sup> Nitrogen-based heterocycles such as pyrimidines constitute a fundamental class of NLO (nonlinear optical allows us to change the color of a light beam, to change its

Received 8 January 2024; revised 29 September 2024; accepted 1 October 2024.  
Available online 15 August 2025

\* Corresponding author.

E-mail addresses: hayder.raheem@uokerbala.edu.iq (H. R. Ali), ahmedwahed@uobaghdad.edu.iq (A. W. Naser).

<https://doi.org/10.21123/2411-7986.5013>

2411-7986/© 2025 The Author(s). Published by College of Science for Women, University of Baghdad. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

shape in space and time, and to create the shortest events ever made by humans) materials because nitrogen atom in pyrimidine plays role of the electron acceptor group in a  $\pi$ -conjugated structure. Furthermore, the lone pair of nitrogen increases its basic character, protonation ability, chelation, and hydrogen bond formation.<sup>12</sup> Pyrimidine nucleobases includes: uracil, thymine and cytosine.<sup>13</sup> The structural diversity and biological importance of pyrimidines have made them attractive targets for synthesis over many years.<sup>14</sup> Condensed heterocyclic compounds with pyrimidine ring are of interest since they include valuable pharmacological substances.<sup>15</sup> Pyrimidine derivatives are found to have a wide range of chemotherapeutic effects including angiogenic, enzyme inhibitory effects and anti-leishmanial activity.<sup>16</sup> Heterocyclic compounds containing nitrogen atoms have a great benefits within the field of drugs and industrial chemistry due to their strong and selective probability to occur hydrogen bonds with protein/enzyme Parts, which are responsible for important biological activities such as antibacterial,<sup>17</sup> anti-proliferative,<sup>18</sup> antitubercular.<sup>19</sup> and antifungal activity.<sup>20</sup> In the present paper, we report the synthesis of some new chalcones, 5,6-dihydropyrimidin-2-ol and 5,6-dihydropyrimidin-2-thiol derivatives bearing 1,2,3-triazoline and investigating their practical and theoretical biological activities.

## Materials and methods

### Experimental methods

All Chemicals were purchased from BDH, Merck, and Fluka. A recorder called M.P. was used to makes use of an electrothermal (m.P.) device. A Shimadzu FT-IR8400S spectrophotometer in the Chemistry Department, College, University of Kerbala, was used to record the FT-IR spectrum data. The <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra are recorded at 500 MHz in Tehran University's central laboratory, with DMSO-d<sub>6</sub> and (TMS) serving as interior standards.

### General method for chalcone derivatives synthesis (2a-h)<sup>21</sup>

Benzaldehydes Such as *m*-hydroxy, *p*-hydroxy, *p*-chloro, *p*-bromo, *p*-nitro, *p*-N,N-dimethyl, and 2,4-dimethoxy benzaldehyde (12 mmol, 0.00014 mg) and Substituted acetophenone involving 1,2,3-triazoline (1) (12 mmol, 0.0046 mg) were dissolved in ethanol (10 mL), and 40% potassium hydroxide solution (10 mL) was added dropwise while stirring at room

temperature over a period of 30 minutes and refluxed for eight to ten hours. The progress of the reaction was monitored by TLC. The solvent was removed on a rotary evaporator under reduced pressure, the residue was poured into ice water, and the product was filtered off and recrystallized from methanol (2a-h), as shown in Scheme 1. Physical properties of compounds (2a-h) are listed in Table 1.

### 2-(N-((1-(4-(3-phenylacryloyl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (2a)

FT-IR (KBr),  $\nu(\text{cm}^{-1})$ : 3286(N-H and O-H vib. Coupling) 3059(C-H)Ar, 2924 and 2862(C-H aliph) 1708(C=O)acid, 1651(C=O)ketone, 1599(C=C), 1529(N=N), 1336(SO<sub>2</sub>)Asym, 1168(SO<sub>2</sub>)Sym, 1224(C-O)Asym, 1118(C-O)Sym. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>), ( $\delta$ ppm): 2.43 (d, 2H, CH<sub>2</sub> triazoline), 3.67(t, 2H, CH<sub>2</sub>-NH), 4.77–4.86 (m, 1H, CH triazoline), 6.76–7.00(m, 2H, CH=C-H), 7.12–7.99 (m, 14H Ar-H and NH-CH<sub>2</sub>), 12.35 (s, 1H,-O-H). <sup>13</sup>C-NMR ( $\delta$  ppm): 44.91(CH<sub>2</sub>-NH), 54.39(CH<sub>2</sub> triazoline), 75.05(CH-N), 119.03(O=C-C=C), 124–145 (C-Ar), 147.78(C=C), 163.92 (O=C-O-H), 195, 45(C=O).








### 2-(N-((1-(4-(3-(4-chlorophenyl)acryloyl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (2b)

FT-IR (KBr),  $\nu(\text{cm}^{-1})$ : 3375(O-H), 3302(N-H), 3061(C-H)Ar, 2928 and 2858(C-H aliph), 1689(C=O)acid, 1633(C=O)ketone, 1599(C=C), 1529(N=N), 1327(SO<sub>2</sub>)Asym, 1170(SO<sub>2</sub>)Sym, 1230(C-O)Asym, 1120(C-O)sym.

### (Z)-2-(N-((1-(4-(3-(4-bromophenyl)acryloyl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (2c)

FT-IR (KBr),  $\nu(\text{cm}^{-1})$ : 3373(O-H), 3271(N-H), 3088(C-H)Ar, 2926 and 2858(C-H aliph) 1681(C=O)acid, 1637(C=O)ketone, 1593(C=C), 1529(N=N), 1325(SO<sub>2</sub>)Asym, 1168(SO<sub>2</sub>)Sym, 1236(C-O), 1120(C-O)Sym. <sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): 2.50 (d, 2H, CH<sub>2</sub> triazoline), 3.47(t, 2H, CH<sub>2</sub>-NH), 4.29–4.34 (m, 1H, CH triazoline), 6.31–6.70(m, 2H, CH=C-H), 7.76–8.08 (m, 13H Ar-H and NH-CH<sub>2</sub>), 12.69 (s,1H,-O-H). <sup>13</sup>C-NMR ( $\delta$  ppm): 45.19(CH<sub>2</sub> -NH), 55.85(CH<sub>2</sub> triazoline), 73.99(CH-N), 119.09(O=C-C=C), 121.08–145.05 (C-Ar), 151.42(C=C), 176.14 (O=C-O-H), 197, 13(C=O).

**Table 1.** Physical properties of compounds (2a-h), (3a-e) and (4a-d).

| No. | Chemical structure  | Chemical formula        | M.W.<br>g/mol | M.P.<br>°C | Yield<br>% | Color      |
|-----|---|-------------------------|---------------|------------|------------|------------|
| 2a  |    | $C_{25}H_{22}N_4O_5S$   | 490.53        | 108–111    | 87         | Brown      |
| 2b  |    | $C_{25}H_{21}ClN_4O_5S$ | 524.98        | 112–113    | 77         | Deep Brown |
| 2c  |    | $C_{25}H_{21}BrN_4O_5S$ | 569.43        | 116–117    | 80         | Brown      |
| 2d  |   | $C_{25}H_{21}N_5O_7S$   | 535.53        | 125–127    | 73         | Brown      |
| 2e  |  | $C_{25}H_{22}N_4O_6S$   | 506.53        | 118–120    | 68         | Pale Brown |
| 2f  |  | $C_{25}H_{22}N_4O_6S$   | 506.53        | 105–106    | 76         | Pale Brown |
| 2g  |  | $C_{27}H_{27}N_5O_5S$   | 533.60        | 122–126    | 82         | Pale Green |

(Continued)



Table 1. Continued.

| No. | Chemical structure | Chemical formula          | M.W.<br>g/mol | M.P.<br>°C | Yield<br>% | Color        |
|-----|--------------------|---------------------------|---------------|------------|------------|--------------|
| 2h  |                    | $C_{27}H_{26}N_4O_7S$     | 550.59        | 128–129    | 72         | Redish Brown |
| 3a  |                    | $C_{26}H_{24}N_6O_5S$     | 532.58        | 172–174    | 54         | red          |
| 3b  |                    | $C_{26}H_{23}ClN_6O_5S$   | 567.02        | 176–178    | 65         | Deep Red     |
| 3c  |                    | $C_{26}H_{23}BrN_6O_5S$   | 611.47        | 184–186    | 56         | Pale Brown   |
| 3d  |                    | $C_{26}H_{23}N_7O_7S$     | 577.57        | 196–198    | 73         | Pale Brown   |
| 3e  |                    | $C_{26}H_{24}N_6O_6S$     | 548.57        | 191–193    | 61         | Green        |
| 4a  |                    | $C_{26}H_{23}ClN_6O_4S_2$ | 583.08        | 203–204    | 70         | Green        |
| 4b  |                    | $C_{26}H_{23}BrN_6O_4S_2$ | 627.53        | 211–212    | 59         | Brown        |

(Continued)

Table 1. Continued.

| No. | Chemical structure | Chemical formula   | M.W. g/mol | M.P. °C | Yield % | Color       |
|-----|--------------------|--|------------|---------|---------|-------------|
| 4c  |                    | C <sub>26</sub> H <sub>23</sub> N <sub>7</sub> O <sub>6</sub> S <sub>2</sub> | 593.63     | 219–220 | 76      | Pale yellow |
| 4d  |                    | C <sub>28</sub> H <sub>29</sub> N <sub>7</sub> O <sub>4</sub> S <sub>2</sub> | 591.71     | 193–194 | 75      | Pale Brown  |

*2-(N-((1-(4-(3-(4-nitrophenyl)acryloyl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (2d)*

FTIR(KBr),  $\nu(\text{cm}^{-1})$ : 3452(O-H), 3377(N-H), 3076(C-H)Ar, 2929 and 2870(C-H aliph), 1714(C=O) acid, 1651(C=O)ketone, 1593(C=C), 1516(N=N), 1450(NO<sub>2</sub>)Assyn, 1338(NO<sub>2</sub>)Sym, 1390(SO<sub>2</sub>)Asym, 1168(SO<sub>2</sub>)Sym, 1220(C-O)Asym, 1136(C-O) Sym.

*2-(N-((1-(4-(3-(3-hydroxyphenyl)acryloyl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (2e)*

FT-IR (KBr),  $\nu(\text{cm}^{-1})$ : 3365(O-H), 3267(N-H), 3064(C-H)Ar, 2926 and 2872(C-H aliph), 1718(C=O)acid, 1651(C=O)ketone, 1595(C=C), 1529(N=N), 1332(SO<sub>2</sub>)Asym, 1165(SO<sub>2</sub>)Sym, 1273(C-O)Asym, 1122(C-O)Sym.

*2-(N-((1-(4-(3-(4-hydroxyphenyl)acryloyl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (2f)*

FT-IR (KBr),  $\nu(\text{cm}^{-1})$ : 3363(O-H), 3217(N-H) 3068(C-H)Ar, 2928 and 2858(C-H aliph), 1718(C=O)acid, 1651(C=O)ketone, 1595(C=C), 1514(N=N), 1332(SO<sub>2</sub>)Asym, 1165(SO<sub>2</sub>)Sym, 1222(C-O)Asym, 1064(C-O)Sym.

*2-(N-((1-(4-(3-(4-(dimethylamino)phenyl)acryloyl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (2g)*

FT-IR (KBr),  $\nu(\text{cm}^{-1})$ : 3392(O-H), 3286(N-H), 3036(C-H)Ar, 2922 and 2858(C-H aliph), 1724(C=O)acid, 1649(C=O)ketone, 1595(C=C),


1525(N=N), 1336(SO<sub>2</sub>)Asym, 1180(SO<sub>2</sub>)Sym, 1230(C-O)Asym, 1124(C-O)Sym. <sup>1</sup>H-NMR: 2.67 (d, 2H, CH<sub>2</sub> triazoline), 3.03(s, 6H, CH<sub>3</sub>), 3.50(t, 2H, CH<sub>2</sub>-NH), 4.91–4.95 (m, 1H, CH triazoline), 5.74–5.86(m, 2H, CH=C-H), 6.10–7.90 (m, 13H Ar-H and NH-CH<sub>2</sub>), 12.76 (s, 1H, O-H). <sup>13</sup>C-NMR ( $\delta$  ppm): 30.01(CH<sub>3</sub>), 42.72(CH<sub>2</sub>-NH), 52.69(CH<sub>2</sub> triazoline), 71.51(CH-N), 112.06(O=C-C=C), 119.09–136.71(C-Ar), 153.56(C=C), 176.92 (O=C-O-H), 196.48(C=O).

*2-(N-((1-(4-(3-(2,4-dimethoxyphenyl)acryloyl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (2h)*

FT-IR (KBr),  $\nu(\text{cm}^{-1})$ : 3433(O-H), 3371(N-H), 3066(C-H)Ar, 2937 and 2847(C-H aliph), 1674(C=O)acid, 1649(C=O)ketone, 1600(C=C), 1510(N=N), 1301(SO<sub>2</sub>)Asym, 1165(SO<sub>2</sub>)Sym, 1213(C-O)Asym, 1114(C-O)Sym.

*General method for 5,6-dihydropyrimidin-2-ol derivatives synthesis of (3a-e)<sup>22</sup>*

A mixture of chalcone (**2a-h**) (0.01 mol), urea (0.01 mol, 0.6 g) was dissolved in ethanol (10 mL). To this, 40% aqueous potassium hydroxide solution (10 mL) was added slowly with constant stirring. The reaction mixture was allowed to reflux on water bath for 8 hours. TLC was monitored to check the completion of reaction. After completion of reaction, the reaction mixture was cooled to room temperature and then poured into ice cold water and neutralized by adding dilute HCl. The obtained precipitate (**3a-e**), as shown in Scheme 1, was filtered, washed with water and dried. The product was recrystallized from ethanol. Physical properties of compounds (**3a-e**) are listed in Table 1.



**Scheme 1.** Route synthesized compounds (2a-h), (3a-e) and (4a-d).

2-(N-((1-(4-(2-oxo-6-phenyl-1,2,5,6-tetrahydropyrimidin-4-yl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (**3a**)

FT-IR (KBr),  $\nu(\text{cm}^{-1})$ : 3389(O-H), 3271(NH), 3095(C-H)Ar, 2949 and 2883(C-H aliph),

1716(C=O)acid, 1653(C=N) pyrimidine, 1606(C=C), 1533(N=N), 1315(SO<sub>2</sub>)Asym, 1180(SO<sub>2</sub>)Sym. <sup>1</sup>H-NMR: 2.49 (d, 2H, CH<sub>2</sub> pyrimidine), 3.25(d, 2H, CH<sub>2</sub>-NH), 3.74 (d, 2H, CH<sub>2</sub> triazoline), 4.28(t, 1H, CH pyrimidine), 4.68–4.74 (m, 1H, CH triazoline), 6.54–8.32 (m, 14H Ar-H and

NH-CH<sub>2</sub>), 10.59 (s, 1H, -O-H), 12.45 (s, 1H, O=C-O-H) carboxyl. <sup>13</sup>C-NMR (δ ppm): 39.26 (CH<sub>2</sub>-NH), 44.44 (CH<sub>2</sub> pyrimidine), 52.11 (CH<sub>2</sub> triazoline), 55.08 (CH pyrimidine), 76.35 (CH triazoline), 110.03–152.52 (C-Ar), 165.24 (C=N pyrimidine), 173, 50 (O=C-O-H).

*2-(N-((1-(4-(6-(4-chlorophenyl)-2-oxo-1,2,5,6-tetrahydropyrimidin-4-yl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (3b)*

FT-IR (KBr), ν(cm<sup>-1</sup>): 3373(O-H), 3296(NH), 3063(C-H)Ar, 2926 and 2860(C-H aliph), 1687(C=O)acid, 1653(C=N) 1595(C=C), 1529(N=N), 1329(SO<sub>2</sub>)Asym, 1180(SO<sub>2</sub>)Sym, 819(C-Cl).

*2-(N-((1-(4-(6-(4-bromophenyl)-2-oxo-1,2,5,6-tetrahydropyrimidin-4-yl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (3c)*

FT-IR (KBr), ν(cm<sup>-1</sup>): 3373(O-H), 3327(NH), 3028(C-H)Ar, 2920 and 2862(C-H aliph), 1691(C=O)acid, 1649(C=N), 1591(C=C), 1514(N=N), 1323(SO<sub>2</sub>)Asym, 1170(SO<sub>2</sub>)Sym, 758(C-Br).

*2-(N-((1-(4-(6-(4-nitrophenyl)-2-oxo-1,2,5,6-tetrahydropyrimidin-4-yl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (3d)*

FT-IR (KBr), ν(cm<sup>-1</sup>): 3373(O-H), 3227(N-H), 3066(C-H)Ar, 2926 and 2860(C-H aliph), 1708(C=O)acid, 1631(C=N)pyrimidine, 1593(C=C), 1516(N=N and Asym NO<sub>2</sub> vib. Coupling), 1327(SO<sub>2</sub> and NO<sub>2</sub> sym vib. Coupling), 1168(SO<sub>2</sub>) Sym.

*2-(N-((1-(4-(6-(3-hydroxyphenyl)-2-oxo-1,2,5,6-tetrahydropyrimidin-4-yl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (3e)*

FT-IR (KBr), ν(cm<sup>-1</sup>): 3381(O-H), 3236(N-H), 3066(C-H)Ar, 2924 and 2858(C-H aliph), 1674(C=O)acid, 1647(C=N)pyrimidine, 1593(C=C), 1518(N=N), 1317(SO<sub>2</sub>)Asym, 1165(SO<sub>2</sub>)Sym. <sup>1</sup>H-NMR: 2.53 (d, 2H, CH<sub>2</sub> pyrimidine), 3.25 (d, 2H, CH<sub>2</sub>-NH), 3.29 (d, 2H, CH<sub>2</sub> triazoline), 4.50 (t, 1H, CH pyrimidine), 4.71–4.77 (m, 1H, CH triazoline), 6.54–8.32 (m, 13H Ar-H and NH-CH<sub>2</sub>), 11.31 (d, 2H, -O-H), 12.75 (s, 1H, O=C-O-H) carboxyl. <sup>13</sup>C-NMR (δ ppm): 34.47 (CH<sub>2</sub>-NH),

44.07 (CH<sub>2</sub> pyrimidine), 51.35 (CH<sub>2</sub> triazoline), 55.08 (CH pyrimidine), 81.10 (CH triazoline), 116.52–151.85 (C-Ar), 165.61 (C=N pyrimidine), 174, 16 (O=C-O-H).

*General method for 5,6-dihydropyrimidin-2-thiol derivatives synthesis of (4a-d)<sup>22</sup>*

A mixture of chalcone (**2b**, **2c**, **2d**, and **2g**) (0.01 mol), thiourea (0.01 mol, 0.6 g) were dissolved in ethanol (10 mL). To this, 40% aqueous potassium hydroxide solution (10 mL) was added slowly with constant stirring. The reaction mixture was allowed to reflux on water bath for 8 h. TLC was monitored to check the completion of reaction. After completion of reaction, the reaction mixture was cooled to room temperature and then poured into ice cold water and neutralized by adding dilute HCl. The precipitate (**4a-d**) as shown in Scheme 1. obtained was filtered, washed with water and dried. The product was recrystallized from ethanol. Physical properties of compounds (**4a-d**) are listed in Table 1.

*2-(N-((1-(4-(6-(4-chlorophenyl)-2-thioxo-1,2,5,6-tetrahydropyrimidin-4-yl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (4a)*

FT-IR (KBr), ν(cm<sup>-1</sup>): 3483(O-H), 3285(N-H) 3061(C-H)Ar, 2926 and 2848(C-H aliph), 2569(S-H), 1687(C=O)acid, 1653(C=N) pyrimidine, 1593(C=C), 1519(N=N), 1321(SO<sub>2</sub>)Asym, 1168(SO<sub>2</sub>)Sym, 1242(C=S)Asym, 823 ν(C-Cl).

*2-(N-((1-(4-(6-(4-bromophenyl)-2-thioxo-1,2,5,6-tetrahydropyrimidin-4-yl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (4b)*

FT-IR (KBr), ν(cm<sup>-1</sup>): 3369(O-H), 3255(N-H), 3063(C-H)Ar, 2924 and 2858(C-H aliph), 2569(S-H), 1681(C=O acid and C=N pyrimidine vib. Overlap), 1593(C=C), 1527(N=N), 1325(SO<sub>2</sub>)Asym, 1168(SO<sub>2</sub>)Sym, 758 ν(C-Br), 1274 (C=S).

*2-(N-((1-(4-(6-(4-nitrophenyl)-2-thioxo-1,2,5,6-tetrahydropyrimidin-4-yl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (4c)*

FT-IR (KBr), ν(cm<sup>-1</sup>): 3458(O-H), 3379(N-H), 3070(C-H)Ar, 2926 and 2850(C-H aliph), 2534(S-H), 1693(C=O)acid, 1654(C=N)pyrimidine, 1595(C=C), 1518(N=N and NO<sub>2</sub> vib. coupling), 1290(SO<sub>2</sub>)Asym, 1166(SO<sub>2</sub>)Sym, 1253(C=S). <sup>1</sup>H-NMR: 2.04 (s, 1H,

SH), 2.48(d, 2H, CH<sub>2</sub> pyrimidine), 3.04 (d, 2H, CH<sub>2</sub> triazoline), 3.77(d, 2H, CH<sub>2</sub>-NH), 4.38(t, 1H, CH pyrimidine), 4.61–4.69 (m, 1H, CH triazoline), 6.54–8.18 (m, 13H Ar-H and NH-CH<sub>2</sub>), 12.09(s, 1H, O=C-O-H). <sup>13</sup>C-NMR (δ ppm): 31.71(CH<sub>2</sub>-NH), 43.76(CH<sub>2</sub> pyrimidine), 52.32(CH<sub>2</sub> triazoline), 64.37(CH pyrimidine), 84.60(CH triazoline), 120.05–146.34(C-Ar), 156.68(C=N pyrimidine), 165, 91(O=C-O-H), 174.54 (C=S).

2-(N-((1-(4-(6-(4-(dimethylamino)phenyl)-2-thioxo-1,2,5,6-tetrahydropyrimidin-4-yl)phenyl)-4,5-dihydro-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)benzoic acid (4d)

FT-IR (KBr), ν(cm<sup>-1</sup>): 3356(O-H), 3255(N-H), 3061(C-H)Ar, 2912 and 2808(C-H aliph), 2602(S-H), 1670(C=O)acid, 1651 (C=N) pyrimidine, 1595(C=C), 1521(N=N), 1338(SO<sub>2</sub>)Asym, 1165(SO<sub>2</sub>)Sym, 1230(C=S). <sup>1</sup>H-NMR: 2.06(s, 1H, SH), 2.48(d, 2H, CH<sub>2</sub> pyrimidine), 3.02(s, 6H, CH<sub>3</sub>), 3.27 (d, 2H, CH<sub>2</sub> triazoline), 3.53(d, 2H, CH<sub>2</sub>-NH), 4.31(t, 1H, CH pyrimidine), 4.64–4.72 (m, 1H, CH triazoline), 6.54–8.04 (m, 13H Ar-H and NH-CH<sub>2</sub>), 13.53(s, 1H, O=C-O-H).

## Results and discussion

Substituted acetophenone involved 1, 2, 3-triazoline (1). By using N-allyl saccharin<sup>23</sup> to cyclize p-acetyl azido benzene, compound (1) was created as a starting material. The synthesis of chalcone derivatives involved the condensation of several benzaldehydes, in the presence of potassium hydroxide 40%. The new bands arise at the range (1651 to 1633) and (1600 to 1593) cm<sup>-1</sup> are because of the (C=O) and (C=C), correspondingly. On the other hand, 5.74 to 7.00 (m, 2H, CH=C-H) and 12.35 to 12.76 (s, 1H, -O-H) were found using <sup>1</sup>H- and <sup>13</sup>C-NMR. and 163.92–176.92 (O=C-O-H), 147.78–153.56 (C=C), and 112.06–119.03 (O=C-C=C). The reaction cyclization of chalcones with urea and thiourea correspondingly, in the presence of aqueous potassium hydroxide solutions,<sup>22</sup> afforded the corresponding 5,6-dihydropyrimidin-2-ol. The results showed the disappearance of ν(C=O) acetophenone group at (1651 to 1633) cm<sup>-1</sup>. And the appearance of new bands is attributed to the ν(C=N) at (1683 to 1647) cm<sup>-1</sup>. The results of <sup>1</sup>H-NMR and <sup>13</sup>C-NMR indicated the 3.74–3.29 (d, 2H, CH<sub>2</sub> pyrimidin-2-ol), 4.28–4.50 (t, 1H, CH pyrimidin-2-ol), 10.59–11.31(s, 1H, OH), and 44.44–44.07 (CH<sub>2</sub> pyrimidine), 55.08 (CH 5,6-dihydropyrimidin-

**Table 2.** Biological activity of some prepared compounds and the control drug.

| Comp.       | <i>S. aureus</i><br>(Gram-positive) | <i>E. coli</i><br>(Gram-negative) |
|-------------|-------------------------------------|-----------------------------------|
| 2d          | -                                   | 19                                |
| 2e          | -                                   | 18                                |
| 2g          | -                                   | 17                                |
| 3a          | 13                                  | 12                                |
| 4c          | 21                                  | 18                                |
| 4d          | 12                                  | 19                                |
| Ceftriaxone | 12                                  | 16                                |
| Control     | -                                   | -                                 |

[Control]: mL at 100 μg; dimethylsulfoxide is the solvent.

(-) No inhibition; (12–16) moderate; and (17–20) high inhibition Zone.

2-ol), (151.85 COH5,6-dihydropyrimidin-2-ol), 165.42–165.61(C=N 5,6-dihydropyrimidin-2-ol) and appeared 3.27–3.04 (d, 2H, CH<sub>2</sub> pyrimidin-2-thiol), 4.31–4.38 (t, 1H, CH 5,6-dihydropyrimidin-2-thiol), and 43.76(CH<sub>2</sub> 5,6-dihydropyrimidin-2-ol), 64.37(5,6-dihydropyrimidin-2-ol), 156.68(C=N 5,6-dihydropyrimidin-2-ol) and 174.54 (C=S). Scheme 1. Shows the route synthesized compounds (2a-h), (3a-e) and (4a-d).


## Biological activity

The disk diffusion method<sup>24</sup> was followed in the execution of the test. One strain of *S. aureus*, a Gram-positive bacterium, and one strain of *E. coli*, a Gram-negative bacterium, were used to evaluate the produced compounds. Petri dishes and prepared agar were autoclaved for 15 minutes at 121 degrees Celsius to sterilize them. The examined microorganisms' broth culture was uniformly injected into the agar plates. Appropriately spaced 6 mm diameter holes were created in the solidified medium, and 100 μl of the produced compounds 1 milligram of the chemical diluted in 1 milliliter of DMSO solvent were placed inside. For 24 hours, these plates were incubated at 37 degrees Celsius. We looked at the inhibitory zones that the different chemicals produced on the bacterium. The results indicated that the newly synthesized derivatives (compounds 2d, 2e, 2g, 4c and 4d) showed enhanced activity against Gram-negative bacteria when compared with that of the control drug (Ceftriaxone), while compound 4c showed enhanced activity against Gram-positive bacteria when compared with that of the control drug (Ceftriaxone) because contain electron with drawing group (NO<sub>2</sub>) which increase biological activity<sup>25–27</sup> illustrated in the Table 2.


### Electrochemical oxidation effect

Measurement of the electrochemical index, evaluation of antioxidant capacity, and exploration of antioxidant substances are all highly promising applications of electrochemical methods. The instruments, which are based on potentiostatic analysis and either cyclic or differential pulse voltammetry, can be flow-


through or stationary. The techniques are well-known for their applicability to food control and for tracking antioxidant capacity levels in various biological matrices and samples. Several researchers have looked into the use of electrochemical techniques that uses to the investigations clinical and botanical patterns in order to determine their antioxidant qualities.<sup>28</sup> As seen in Table 1, some of the new derivatives in this




**Fig. 1.** Shows a decrease the peak of current in the cyclic voltammogram at (+1) v of chemical [2d] at 1000  $\mu$ /L con. within the blood serum medium via GCE/CNT and Silver/Silver chloride as reference electrodes.



**Fig. 2.** The CV of chemical [4b] at 1000  $\mu$ /L conc. Within the blood serum medium, with an oxidation current peak at (+1.2) v, using GCE/CNT and Silver/Silver chloride as reference electrodes.



**Fig. 3.** CV of chemical [2g] in blood serum medium at 1000  $\mu\text{L}$  concentration, with Ag/AgCl and GCE/CNT serving as reference electrodes. revealed two peaks for the current rate of oxidation at (-0.2) and (+1.2) volts.



**Fig. 4.** CV of chemical [3b] in blood serum medium at 1000  $\mu\text{L}$  concentration, with Ag/AgCl and GCE/CNT serving as reference electrodes.

investigation [2d, 2e, 2g, 4c, and 4d] possess strong antimicrobial properties. While some of them had a modest degree and were good antioxidants than the others.

$2g > 4d > 3b > 4b > 3d > 2d$

The results are arranged in terms of their effectiveness as antioxidant from high antioxidant to low

antioxidant respectively. The results showed that compounds (2g) that having donating group (N,N-dimethyl) in para position and (4d) having donating group (2,4-dimethoxy) are a good antioxidant with medical uses because they contain one oxidation beak, compounds (3b) and (4b) are actual average against oxidation stress because they have two oxidation peaks, while compounds (3d) and (2d) that having electron withdrawn in position para (*p*-nitro)






Fig. 5. GCE/CNT and Ag/AgCl as reference electrodes, CV of chemical [3d] at 1000  $\mu$ /L conc. Within the blood serum medium.





Fig. 6. GCE/CNT and Silver/Silver chloride as reference electrodes, CV of chemical [4d] at 1000  $\mu$ /L conc. Within the blood serum medium.

are highly toxic and are not recommended to be used as an antioxidant in the therapeutic processes because there are four oxidation peaks as shown in Figs. 1 to 6.

#### Molecular docking studies

The molecular docking studies were performed using PyRx and Biovia Discovery Studio 2021 client



for the current studies, the target X-ray structure of *E. coli* as receptor (PDB ID: 6ul7) was taken from protein data bank(PDB) website (<https://www.rcsb.org/>). The ligand and the protein were converted to the PDBQT format using PyRx, the water molecules and the hate atom were removed. The docking were carried out by using Biovia Discovery Studio 2021 client software and we found specific and non-specific interaction through the linked. The binding energy,



**Fig. 7.** The binding interaction of receptor (PDB ID: 6ul7) with the ligand (3c) with 2D and 3D shape.

bond length and type of interaction between ligand and protein were measured.<sup>29–32</sup> Tables 3 and 5 show the estimated free energy in (kcal/mol) for the prepared compounds with targets proteins. Tables 4 and 6 show docking scores estimated binding energy (kcal/mol), Bonds length (Å) and interaction types with target *E. coli* as receptor (PDB ID: 6ul7).<sup>33</sup>

All seventeen prepared compounds were studied for their molecular docking using the (PyRx and Biovia Discovery Studio 2021 client) program against one type of target, *E. coli*. The results showed that the prepared derivatives **3c** and **4b** give a higher activity than the other derivatives. Figs. 7 and 8 show the 2D and 3D of ligands **3c** and **4b** with receptor (PDB ID: 6ul7).



**Fig. 8.** The binding interaction of receptor (PDB ID: 6ul7) with the ligand (4b) with 2D and 3D shape.

**Table 3.** Compounds (3a-e) docking scores with the receptor (PDB ID: 6ul7).

| Comp. | Estimated energy (kcal/mol) |
|-------|-----------------------------|
| 3a    | -8.4                        |
| 3b    | -7.9                        |
| 3c    | -8.8                        |
| 3d    | -8.5                        |
| 3e    | -8.5                        |

**Table 4.** Compound 3c bond length and interaction type with receptor.

| Length of Bond (Å) | Interaction type                 |
|--------------------|----------------------------------|
| 4.01               | Conventional hydrogen bond       |
| 4.05               | Conventional hydrogen bond       |
| 5.60               | Pi-Cation                        |
| 4.85               | Pi-Cation                        |
| 6.46               | Pi-Cation                        |
| 4.23               | Pi-Alkyl                         |
| 5.15               | Pi-Alkyl                         |
| 4.09               | Pi-Alkyl                         |
| 4.74               | Pi-Alkyl                         |
| 4.54               | Pi-Alkyl                         |
| 6.68               | Pi-Alkyl                         |
| 4.59               | Pi-Alkyl                         |
| 4.61               | Unfavourable Positive - positive |
| 4.51               | Unfavourable Positive - positive |

**Table 5.** Compounds (4a-d) docking scores with the receptor (PDB ID: 6ul7).

| Comp. | Estimated energy (kcal/mol) |
|-------|-----------------------------|
| 4a    | -8.3                        |
| 4b    | -8.8                        |
| 4c    | -8.3                        |
| 4d    | -6.7                        |

**Table 6.** Compound 4b bond length and interaction type with receptor.

| Length of Bond (Å) | Interaction type           |
|--------------------|----------------------------|
| 6.99               | Conventional hydrogen bond |
| 3.36               | Conventional hydrogen bond |
| 5.48               | Conventional hydrogen bond |
| 5.55               | Conventional hydrogen bond |
| 3.68               | Conventional hydrogen bond |
| 6.72               | Van der waals              |
| 4.65               | Pi-Alkyl                   |
| 5.83               | Pi-Cation                  |
| 5.55               | Pi-Cation                  |
| 7.34               | Pi-Cation                  |
| 4.91               | Pi-Cation                  |
| 6.34               | Pi-Cation                  |
| 6.40               | Pi-Cation                  |
| 4.76               | Pi-Cation                  |

## Conclusion

The following series of (compounds **3a-e**) and (**4a-d**) produced derivatives were utilized to use Pyrex - virtual Screening Toll and BIOVIO Discovery Stu-

dio to dock to the putative binding site of *E. coli*. They all demonstrated encouraging binding affinities, which may indicate a robust binding association. Compounds **2f**, **3c**, and **4b** showed the highest potential binding affinity among them. In comparison to Gram-positive bacteria, the synthetic chalcone, pyrimidin-2-ol, and pyrimidin-2-thiol seemed to have a greater effect on *E. coli* bacteria. Compounds **3a** and **4c** of Pyrimidin-2-ol were shown to have greater activity versus *S. aureus* than Ceftriaxone, while the derivatives **2d**, **2e**, **2g**, **4c**, and **4d** were discovered to have superior activity against Gram-negative bacteria than Ceftriaxone. Compound **2d** showed reduction activity whereas the other prepared selected compounds demonstrated antioxidant activity.

## Acknowledgment

Authors would like to express sincere thanks to the Chemistry Department at the University of Baghdad, College of Science for its outstanding assistance and for giving the tools needed to carry out this investigation.

The authors express their gratitude to the Faculty of Science at the University of Tehran, Iran, for their invaluable support in  $^1\text{H-NMR}$  and  $^{13}\text{C-NMR}$ . We sincerely thank Dr. Muhammad Mizher Radhi of the Medicine Faculty at University of Middle Technical in Iraq for his help with the analysis of electrochemical oxidation.

## Authors' declaration

- Conflicts of Interest: None.
- We hereby confirm that all the figures and tables in the manuscript are ours. Furthermore, figures and images, that are not ours, have been included with the necessary permission for re-publication, which is attached to the manuscript.
- No animal studies are present in the manuscript.
- No human studies are present in the manuscript.
- Ethical Clearance: The project was approved by the local ethical committee at University of Baghdad.

## Authors' contribution statement

All the chemical aspects including compounds synthesis, characterization and antioxidant activity measurements were performed by H. R. A. and A. W. N. The molecular docking study including docking procedure and 2D and 3D visualization were done by H. R. A.



## References

- Saleh SS, AL-Salihi SS, Mohammed IA. Biological activity Study for some heterocyclic compounds and their impact on the gram positive and negative bacteria. *Energy Procedia*. 2019;157:296–306. <https://doi.org/10.1016/j.egypro.2018.11.194>.
- Mirzaei S, Hadizadeh F, Eisvand F, Mosaffa F, Ghodsi R. Synthesis, structure-activity relationship and molecular docking studies of novel quinoline-chalcone hybrids as potential anticancer agents and tubulin inhibitors. *J Mol Struct*. 2020;1202(1):1–13. <https://doi.org/10.1016/j.molstruc.2019.127310>.
- Jain S, Kumar S, Lamba BY, Patra J, Mahindroo N. Nanocatalysts: Applications in synthesis of chalcones—a review. *Synth Commun*. 2021;51(1):1–12. <https://doi.org/10.1080/00397911.2020.1817941>.
- Kakati D, Sarma JC. Microwave assisted solvent free synthesis of 1,3-diphenylpropenones. *Chem Cent J*. 2011;5(1):1–5. <https://doi.org/10.1186/1752-153X-5-8>.
- Khan SA, Asiri AM, Al-Ghamdi NSM, Asad M, Zayed MEM, El-roby SAK, *et al*. Microwave assisted synthesis of chalcone and its polycyclic heterocyclic analogues as promising antibacterial agents: In vitro, in silico and DFT studies. *J Mol Struct*. 2019;1190:77–85. <https://doi.org/10.1016/j.molstruc.2019.04.046>.
- Damas L, Rodrigues FMS, Gonzalez ACS, Carrilho RMB, Pineiro M, Pereira MM. Sequential catalytic carbonylation reactions for sustainable synthesis of biologically relevant entities. *J Organomet Chem*. 2020;923:1–7. <https://doi.org/10.1016/j.jorganchem.2020.121417>.
- Pragathi YJ, Veronica D, Anitha K, Rao MVB, Raju RR. Synthesis and biological evaluation of chalcone derivatives of 1,2,4-thiadiazol-benzo[d]imidazol-2-yl)quinolin-2(1H)-one as anti-cancer agents. *Chem Data Collect*. 2020;1–8. <https://doi.org/10.1016/j.cdc.2020.100556>.
- Higgs J, Wasowski C, Marcos A, Juki M, Pavan CH, Gobec S, *et al*. Chalcone derivatives: Synthesis, in vitro and in vivo evaluation of their anti-anxiety, anti-depression and analgesic effects. *Heliyon*. 2019;5(3):1–35. <https://doi.org/10.1016/j.heliyon.2019.e01376>.
- Jin H, Jiang X, Yoo H, Wang T, Sung GC, Choi U, *et al*. Synthesis of Chalcone-Derived Heteroaromatics with Antibacterial Activities. *ChemistrySelect*. 2020;5(40):12421–12424. <https://doi.org/10.1002/slct.202003397>.
- Burmaoglu S, Yilmaz AO, Polat MF, Kaya R, Gulcin İ, Algul O. Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and  $\alpha$ -glycosidase inhibitors. *Bioorg Chem*. 2019;85:191–197. <https://doi.org/10.1016/j.bioorg.2018.12.035>.
- Bori J, Mahata S, Manivannan V. A new route for the synthesis of 2,4-bis(2-pyridyl)-6-(pyridyl)pyrimidines: Synthesis and characterization of Co(II), Ni(II) complexes of 2,4,6-tris(2-pyridyl)pyrimidine. *Inorganica Chim Acta*. 2020;506:1–7. <https://doi.org/10.1016/j.ica.2020.119506>.
- Khan I, Khalid M, Adeel M, Khan MU, Khan MS, Ahmad N, *et al*. Palladium-catalyzed synthesis of pyrimidine substituted diaryl ethers through Suzuki Miyaura coupling reactions: Experimental and DFT studies. *Int J Light Electron Opt*. 2020;219:1–9. <https://doi.org/10.1016/j.jileo.2020.165285>.
- Ganyecz Á, Kállay M, Csontos J. Thermochemistry of Uracil, Thymine, Cytosine, and Adenine. *J Phys Chem A*. 2019;123(18):4057–4067. <https://doi.org/10.1021/acs.jpca.9b02061>.
- Li C, Liu Y, Ren X, Tan Y, Jin L, Zhou X. Design, Synthesis and Bioactivity of Novel Pyrimidine Sulfonate Esters Containing Thioether Moiety. *Int J Mol Sci*. 2023;24(5):1–18. <https://doi.org/10.3390/ijms24054691>.
- Abd-Elhussain TH, Farhan MS. Synthesis of New Pyrimidine Derivatives From 3-Acetylcoumarin–Chalcone Hybrid and Evaluation Their Antimicrobial Activity. *Iraqi J Pharm Sci*. 2024;33(1):33–45. <https://doi.org/10.31351/vol33iss1pp33-45>.
- Youssef AMS, Fouda AM, Faty RM. Microwave assisted synthesis of some new thiazolopyrimidine and pyrimidothiazolopyrimidopyrimidine derivatives with potential antimicrobial activity. *Chem Cent J*. 2018;12(1):1–15. <https://doi.org/10.1186/s13065-018-0419-0>.
- Güngör T. Microwave assisted, sequential two-step, one-pot synthesis of novel imidazo[1,2-a] pyrimidine containing tri/tetrasubstituted imidazole derivatives. *Turkish J Chem*. 2021;45(1):219–230. <https://doi.org/10.3906/KIM-2009-40>.
- Han Y, Tian Y, Wang R, Fu S, Jiang J, Dong J, *et al*. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition. *Bioorg Chem*. 2020;104:1–12. <https://doi.org/10.1016/j.bioorg.2020.104197>.
- Sureja DK, Dholakia SP, Vadalia KR. Conventional and microwave assisted synthesis of novel pyrimidine derivatives as antimicrobial and antitubercular agent. *Der Pharm Lett*. 2016;8(9):181–186. <https://doi.org/10.1021/acsomega.1c04411>.
- Bhadraiah UK. Novel One-Pot Three-Component Synthesis, Antimicrobial, and Antioxidant Evaluation. *Biointerface Res Appl Chem*. 2021;11(5):12925–12936. <https://doi.org/10.33263/BRIAC115.1292512936>.
- Salotra R, Utreja D, Sharma P. A Convenient One-Pot Synthesis of Chalcones and Their Derivatives and Their Antimicrobial Activity. *Russ J Org Chem*. 2020;56(12):2207–2211. <https://doi.org/10.1134/S1070428020120258>.
- Sahoo BM, Rajeswari M, Jnyanaranjan P, Binayani S. Green expedient synthesis of pyrimidine derivatives via chalcones and evaluation of their anthelmintic activity. *Indian J Pharm Educ Res*. 2017;51(4):S700–S706. <https://doi.org/10.5530/ijper.51.4s.101>.
- Shneshil MK, Naser AW, Aowda SA. Synthesis of some saccharin derivatives containing 1, 2, 3-triazoline ring. *Int J ChemTech Res*. 2016;9(9):389–393.
- Abood ZH, Ali HR, Qabel HA, Rasheed OH. Microwave synthesis and antibacterial activities of some imidazolidine derivatives containing 1, 3, 4-oxadiazole moiety. *Asian J Chem*. 2018;30(3):546–550. <https://doi.org/10.14233/ajchem.2018.20970>.
- Arulkumaran R, Vijayakumar S, Sakthnathan SP, Kamalakkannan D, Ranganathan K, Suresh R, *et al*. Preheated fly-ash catalyzed aldol condensation: Efficient synthesis of chalcones and antimicrobial activities of some 3-thienyl chalcones. *J Chil Chem Soc*. 2013;58(2):1684–1690. <http://dx.doi.org/10.4067/S0717-97072013000200008>.
- K Saini KR, Choudhary SA, Joshi YC, Joshi P. Solvent Free Synthesis of Chalcones and their Antibacterial Activities. *E-Journal Chem*. 2005;2(4):224–227. <https://doi.org/10.1155/2005/294094>.
- Khan SA, Asiri AM. Green synthesis, characterization and biological evaluation of novel chalcones as anti bacterial agents. *Arab J Chem*. 2017;10:S2890–S2895. <http://dx.doi.org/10.1016/j.arabjc.2013.11.018>.

28. Abdullah AL, Radhi MM, Khelkal IN, Naji EN. Azithromycin nanoparticles: Cyclic voltammetric study in human blood serum samples at electrochemical analysis. *Rom J Neurol Rev Rom Neurol*. 2020;19(1):5–11. <https://doi.org/10.37897/RJN.2020.1.1>.
29. Aarjane M, Slassi S, Ghaleb A, Tazi B, Amine A. Synthesis, biological evaluation, molecular docking and in silico ADMET screening studies of novel isoxazoline derivatives from acridone. *Arab J Chem*. 2021;14(4):1–13. <https://doi.org/10.1016/j.arabjc.2021.103057>.
30. Singh R, Bansal R. 16,17-N'-(alkyl/arylsulfonyl)pyrazoline substituted neuroprotective heterosteroids: Synthesis, molecular docking and preclinical efficacy/toxicity studies in rodents. *Steroids*. 2019;148(4):114–124. <https://doi.org/10.1016/j.steroids.2019.05.002>.
31. Al-Jeilawi OHR, Oleiwi AQ. Preparation, characterization, antioxidant activity of 1-(2-furoyl) thiourea derivatives and study the molecular docking of them as potent inhibitors of Urease enzyme. *Baghdad Sci J*. 2023;20(3):994–1011. <https://doi.org/10.21123/bsj.2023.7745>.
32. Roesma DI, Hanif MM. Cytotoxic Activities, Determining Toxin, and Molecular Docking of Ovary Pufferfish (*Tetraodon leiurus*) in Singkarak Lake as Cancer Chemoprevention Candidate. *Baghdad Sci J*. 2023;20(6):2373–2384. <https://doi.org/10.21123/bsj.2023.8785>.
33. Hussen NH. Synthesis, characterization, molecular docking, ADMET prediction, and anti-inflammatory activity of some Schiff bases derived from salicylaldehyde as a potential cyclooxygenase inhibitor. *Baghdad Sci J*. 2023;20(5):1662–1674. <https://doi.org/10.21123/bsj.2023.7405>.

# تحضير و دراسة الفعالية البيولوجية والالتحام الجزيئي لبعض الجالكونات الجديدة ومشتقات 5,6-ثنائي هايدرو بيريميدين-2-أول و 5,6-ثنائي هايدرو بيريميدين-2-ثايول الحاملة 1،2،3- تريازولين

حيدر رحيم علي<sup>1</sup>، احمد وحيد ناصر<sup>2</sup>

<sup>1</sup>قسم الكيمياء، كلية العلوم، جامعة كربلاء، كربلاء، العراق.

<sup>2</sup>قسم الكيمياء، كلية العلوم، جامعة بغداد، بغداد، العراق.

## المستخلص

في هذا العمل تم تحضير انواع مختلفة من المركبات الجديدة مثل الجالكونات، بيريميدين-2-أول و بيريميدين-2-ثايول الحاوية على حلقة 1,2,3-تريازولين. حيث تم استخدام المركب (1) كبادئ حيث تم تكثيفه مع مجموعة من الالديهيدات الاروماتية وهي البنزلديهيد، بارا-كلورو بنزلديهيد، بارا-برومو بنزلديهيد، بارا-نايترو بنزلديهيد، ميتا-نايترو بنزلديهيد، بارا-N,N-ثنائي مثيل بنزلديهيد و 2,4-ثنائي ميثوكسي بنزلديهيد بوجود قاعدة 40% KOH لتعطي مشتقات الجالكونات (a-h2). وتم تفاعل بعض الجالكونات (a-e2) مع اليوريا بوجود هيدروكسيد الصوديوم لتعطي مشتقات بيريميدين-2-أول (a-e3). وأيضا تم تفاعل بعض الجالكونات (a-d2) مع الثايوريا بوجود قاعدة هيدروكسيد البوتاسيوم للحصول على مشتقات بيريميدين-2-ثايول (4a-d). تم تشخيص المركبات المحضرة طيفيا بواسطة تقنيات (الاشعة تحت الحمراء وطيف الرنين النووي المغناطيسي للبروتون والكربون). أظهرت المركبات المحضرة فعالية بيولوجية جيدة كمضادات للبكتيريا ومضادات للأكسدة. وقد أظهرت دراسات الالتحام الجزيئي بواسطة برنامج PyRx و Discovery studio 2021 (client) باستخدام البروتين 6uI7 مع المركبات المحضرة الجديدة مواقع التهام جيدة وقد أظهرت النتائج الحالية ان المركبات المحضرة تمتلك فعالية بيولوجية افضل مع البكتيريا السالبة لصبغة كرام (Escherichia Coli).

**الكلمات المفتاحية:** مضادات البكتيريا، مضادات الأكسدة، جالكون، الالتحام الجزيئي، بيريميدين.